| Schedule of Share Capital |
Authorized: Unlimited number of no par value common shares
|
|
|
Share Capital Number |
|
|
Share Capital Amount |
| |
|
|
|
|
|
$ |
| |
Balance - December 31, 2019 |
|
|
39,907,681 |
|
|
|
194,217 |
| |
Issued pursuant to vendor |
|
|
501,148 |
|
|
|
250 |
| |
Issued pursuant to "At the Market" (ATM) equity agreement |
(c) |
|
4,408,048 |
|
|
|
2,072 |
| |
Issued pursuant to agency agreements |
(d) |
|
19,014,504 |
|
|
|
10,497 |
| |
Equity Offering-broker warrants |
|
|
0 |
|
|
|
(1,029 |
) | |
Common share equivalents converted |
(d) |
|
11,500,000 |
|
|
|
1 |
| |
Share issue expense |
|
|
0 |
|
|
|
(488 |
) | |
Warrants exercised |
|
|
7,853,462 |
|
|
|
8,628 |
| |
Balance - December 31, 2020 |
|
|
83,184,843 |
|
|
|
214,148 |
| |
Derivative warrants exercised |
|
|
8,000,000 |
|
|
|
8,000 |
| |
Derivative warrants exercised - fair value adjustment |
|
|
0 |
|
|
|
15,722 |
| |
January 2021 Equity Offering, net of issuance costs |
(a) |
|
7,419,354 |
|
|
|
7,211 |
| |
January 2021 Equity Offering-broker warrants |
|
|
|
|
|
|
(1,384 |
) | |
February 2021 Equity Offering, net of issuance costs |
(b) |
|
9,585,250 |
|
|
|
15,165 |
| |
February 2021 Equity Offering-broker warrants |
|
|
|
|
|
|
(1,238 |
) | |
Equity warrants exercised |
|
|
1,318,675 |
|
|
|
2,979 |
| |
Options exercised |
|
|
19,568 |
|
|
|
27 |
| |
Issued pursuant to ATM equity agreement |
(c) |
|
1,600,000 |
|
|
|
2,709 |
| |
Issuance of common shares to consultant |
|
|
75,000 |
|
|
|
25 |
| |
Balance - December 31, 2021 |
|
|
111,202,690 |
|
|
|
263,364 |
|
|
| Schedule of Offering of Securities with H.C. Wainwright |
During 2020, the Company completed 3 separate offerings of securities pursuant to an agency agreement with H.C. Wainwright (“Wainwright”) which are summarized below:
|
|
|
|
Share Capital Number |
|
|
Share Capital Amount |
|
|
Common Share Equivalents |
|
|
Common Share Purchase Warrants |
|
|
Conversion price of the Warrants |
| |
|
|
|
|
|
|
$ |
|
|
|
|
|
|
|
|
$ |
| |
June, 2020 Offering |
|
|
|
6,500,000 |
|
|
|
18,000 |
|
|
|
11,500,000 |
|
|
|
9,000,000 |
|
|
|
1.00 |
| |
Allocation to warrant derivative liability |
|
|
|
|
|
|
|
(9,709 |
) |
|
|
|
|
|
|
|
|
|
|
|
| |
May, 2020 Offering |
|
|
|
5,514,504 |
|
|
|
2,000 |
|
|
|
|
|
|
|
2,757,252 |
|
|
|
0.30 |
| |
Allocation to warrant derivative liability |
|
|
|
|
|
|
|
(508 |
) |
|
|
|
|
|
|
|
|
|
|
|
| |
March, 2020 Offering |
|
|
|
7,000,000 |
|
|
|
1,190 |
|
|
|
|
|
|
|
3,500,000 |
|
|
|
0.19 |
| |
Allocation to warrant derivative liability |
|
|
|
|
|
|
|
(476 |
) |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
19,014,504 |
|
|
|
10,497 |
|
|
|
11,500,000 |
|
|
|
15,257,252 |
|
|
|
|
| |
Conversion price of Common Share Equivalents |
|
|
$0.0001
|
|